BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang R, Gao Y, Liu A, Zhai G. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances. J Drug Target 2021;29:687-702. [PMID: 33474998 DOI: 10.1080/1061186X.2021.1878366] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Onugwu AL, Nwagwu CS, Onugwu OS, Echezona AC, Agbo CP, Ihim SA, Emeh P, Nnamani PO, Attama AA, Khutoryanskiy VV. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases. J Control Release 2023;354:465-88. [PMID: 36642250 DOI: 10.1016/j.jconrel.2023.01.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cong YY, Fan B, Zhang ZY, Li GY. Implantable sustained-release drug delivery systems: a revolution for ocular therapeutics. Int Ophthalmol 2023. [PMID: 36715956 DOI: 10.1007/s10792-023-02637-x] [Reference Citation Analysis]
3 Chen X, Yang R, Shen J, Huang Q, Wu Z. Research Progress of Bioinspired Nanostructured Systems for the Treatment of Ocular Disorders. Pharmaceuticals (Basel) 2023;16. [PMID: 36678597 DOI: 10.3390/ph16010096] [Reference Citation Analysis]
4 Zhao L, Ling L, Lu J, Jiang F, Sun J, Zhang Z, Huang Y, Liu X, Zhu Y, Fu X, Peng S, Yuan W, Zhao R, Zhang Z. Reactive oxygen species‐responsive mitochondria‐targeted liposomal quercetin attenuates retinal ischemia–reperfusion injury via regulating SIRT1 / FOXO3A and p38 MAPK signaling pathways. Bioengineering & Transla Med 2022. [DOI: 10.1002/btm2.10460] [Reference Citation Analysis]
5 Ana RD, Fonseca J, Karczewski J, Silva AM, Zielińska A, Souto EB. Lipid-Based Nanoparticulate Systems for the Ocular Delivery of Bioactives with Anti-Inflammatory Properties. IJMS 2022;23:12102. [DOI: 10.3390/ijms232012102] [Reference Citation Analysis]
6 Das B, Nayak AK, Mallick S. Lipid-based nanocarriers for ocular drug delivery: An updated review. Journal of Drug Delivery Science and Technology 2022;76:103780. [DOI: 10.1016/j.jddst.2022.103780] [Reference Citation Analysis]
7 Salman A, Kantor A, Mcclements ME, Marfany G, Trigueros S, Maclaren RE. Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations. Pharmaceutics 2022;14:1842. [DOI: 10.3390/pharmaceutics14091842] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Farhat W, Yeung V, Ross A, Kahale F, Boychev N, Kuang L, Chen L, Ciolino JB. Advances in biomaterials for the treatment of retinoblastoma. Biomater Sci 2022. [PMID: 35959730 DOI: 10.1039/d2bm01005d] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 H. El-kamel A, A. Ashour A. Recent Strategies for Ocular Drug Delivery: Promises and Challenges. Advances in Drug Delivery Methods [Working Title] 2022. [DOI: 10.5772/intechopen.106335] [Reference Citation Analysis]
10 Yang C, Yang J, Lu A, Gong J, Yang Y, Lin X, Li M, Xu H. Nanoparticles in ocular applications and their potential toxicity. Front Mol Biosci 2022;9:931759. [DOI: 10.3389/fmolb.2022.931759] [Reference Citation Analysis]
11 Tsai CH, Hoang LN, Lin CC, Pan LC, Wu CL, Lin IC, Wang PY, Tseng CL. Evaluation of Topical and Subconjunctival Injection of Hyaluronic Acid-Coated Nanoparticles for Drug Delivery to Posterior Eye. Pharmaceutics 2022;14:1253. [PMID: 35745825 DOI: 10.3390/pharmaceutics14061253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Razavi MS, Ebrahimnejad P, Fatahi Y, D'Emanuele A, Dinarvand R. Recent Developments of Nanostructures for the Ocular Delivery of Natural Compounds. Front Chem 2022;10:850757. [PMID: 35494641 DOI: 10.3389/fchem.2022.850757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Natsaridis E, Gkartziou F, Mourtas S, Stuart MCA, Kolonitsiou F, Klepetsanis P, Spiliopoulou I, Antimisiaris SG. Moxifloxacin Liposomes: Effect of Liposome Preparation Method on Physicochemical Properties and Antimicrobial Activity against Staphylococcus epidermidis. Pharmaceutics 2022;14:370. [DOI: 10.3390/pharmaceutics14020370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Bonilla L, Espina M, Severino P, Cano A, Ettcheto M, Camins A, García ML, Souto EB, Sánchez-López E. Lipid Nanoparticles for the Posterior Eye Segment. Pharmaceutics 2021;14:90. [PMID: 35056986 DOI: 10.3390/pharmaceutics14010090] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
15 Abdelmonem R, Elhabal SF, Abdelmalak NS, El-Nabarawi MA, Teaima MH. Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study. Pharmaceutics 2021;13:221. [PMID: 33562785 DOI: 10.3390/pharmaceutics13020221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]